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Abstract
Acute pancreatitis results from a sequence of events that involve
the systemic inflammatory response. Activated C has multiple anti-
inflammatory activities and may attenuate the degree of pancreatic
injury and systemic organ dysfunction when infused early in
pancreatitis
Acute pancreatitis results from a sequence of pathologic
events that involves the systemic inflammatory response
[1,2]. The initial event is activation and retention of digestive
enzymes in the acinar cells, with subsequent cellular injury. In
addition, the acinar cells release inflammatory mediators,
which leads to recruitment of neutrophils, formation of free
radicals, and activation of the complement system. The
neutrophils and macrophages generate additional cytokines,
nitric oxide, platelet-activating factor (PAF), and other sub-
stances. The amplified inflammatory response exacerbates
the pancreatic injury, causing evolution from an edematous to
a necrotic pancreas. Spillage of the inflammatory mediators
into the systemic circulation produces organ failure. The
importance of the inflammatory cascade in this process is
evidenced by the correlation of serum IL-6 with disease
severity in acute pancreatitis [3].
Multiple experimental studies have examined the role of
therapies directed at modulating the inflammatory response in
acute pancreatitis. The hypothesis is that interventions,
applied early in the course of pancreatitis, can attenuate the
severity of pancreatic injury and the associated systemic
organ dysfunction. Agents directed at tumor necrosis factor
(TNF), IL-1, nuclear factor-κB, inhibitors of lipid peroxidation,
and PAF are among those that have been demonstrated to
reduce the severity of pancreatic injury in experimental models
[1]. The PAF antagonist lexipafant has also been studied in
clinical pancreatitis. However, in a large multicenter trial [4]
administration of lexipafant did not result in a significant
decrease in mortality or in the severity of the pancreatitis.
Activated recombinant protein C (APC), a derivative of a
naturally occurring anticoagulant, reduces mortality in severe
sepsis [5]. In addition to its anticoagulant and profibrinolytic
properties, APC appears to modulate the inflammatory
response through multiple other mechanisms [6,7]. It has
direct effects on neutrophil integrin expression and
neutrophil–endothelial cell interactions. Inhibition of nuclear
factor-κB activation, TNF release, and induction of nitric oxide
synthetase have also been demonstrated. In addition, APC
also appears to have an antiapoptotic effect. These
observations have led to the utilization of APC in other
syndromes in which inflammation and neutrophil mediated
injury play central roles, such as reperfusion, and spinal cord
and radiation injury.
A study by Yamanel and coworkers [8], presented in this
issue of Critical Care, examines the role played by APC in
reducing pancreatic injury in a taurocharate induced model of
acute pancreatitis. APC given 6 hours after the induction of
pancreatitis significantly reduced acinar necrosis, tissue
edema, fat necrosis, and inflammatory infiltration compared
with controls. However, tissue hemorrhage scores were not
different between groups. These changes were associated
with a reduction in serum TNF, IL-6, and amylase levels.
These results suggest that APC may reduce the inflammatory
process associated with pancreatitis. As is the case with
severe sepsis, it is difficult to determine which mechanisms of
action play the primary role in ameliorating tissue injury in this
model. The observation that hemorrhage scores were not
reduced, in concert with the other pathologic findings, is a
matter of concern. The authors interpretation is that this
finding suggests an ‘intact coagulation system’. An alternative
perspective is that, in the presence of decreases in all other
parameters of histologic injury, the lack of a parallel change in
the hemorrhage score indicates an increased bleeding risk
associated with APC. The relative importance of this
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complication is not clear, given the lower systemic cytokine
and amylase levels in the APC treated animals. One element
missing in the study is a histopathologic score at 6 hours
before the administration of APC. Whether APC attenuates
the progression from edematous pancreatitis to necrotizing
pancreatitis, or whether it limits the severity of established
necrotizing pancreatitis has important clinical implications.
Indeed, one explanation for the therapeutic failure of the PAF
antagonist lexipafant is that it might have been administered
too late in the clinical course to be of benefit.
The development of a secondary infection in necrotic
pancreatic tissue is an important complication that
contributes to morbidity and mortality in acute pancreatitis
[9]. Translocation of enteric bacteria from the intestine is
postulated to play an important role in the development of this
complication. In the study by Yamanel and coworkers [8],
APC was also found to reduce significantly the incidence of
culture positive mesenteric lymph nodes and pancreatic
tissue. The authors suggested that this may be related to
APC induced downregulation in inducible nitric oxide
synthase activity. However, the role of nitric oxide in bacterial
translocation in pancreatitis is controversial. Others have
suggested that nitric oxide substrates may reduce bacterial
translocation by preserving microvascular blood flow [10]. To
the extent that this mechanism is important in maintaining the
integrity of the intestinal barrier, the benefit observed with
APC may have been related to its effects in reducing
leukocyte–endothelial cell interactions, thereby improving the
intestinal microcirculation [11].
The data from the study by Yamanel and coworkers [8] are
preliminary and require confirmation in other models of
pancreatitis. It would also seem important to determine
whether the benefit of APC, if any, in experimental acute
pancreatitis occurs before or after the development of acute
necrotizing pancreatitis. As currently approved, whether in the
USA or Europe, APC is utilized for established severe sepsis
with complications. In contrast, the study presented in this
issue, as well as much of the experimental work in this area,
represents an effort to intervene early in pancreatitis in order
to reduce the progression to severe necrotizing pancreatitis,
with its attendant complications [1,12]. The concept of
utilizing APC prophylactically in a clinical syndrome represents
a new and intriguing application of this agent.
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